View ValuationTwist Bioscience 향후 성장Future 기준 점검 1/6Twist Bioscience은 연간 수입과 매출이 각각 50.6%와 13.7% 증가할 것으로 예상되고 EPS는 연간 44.3%만큼 증가할 것으로 예상됩니다.핵심 정보50.6%이익 성장률44.28%EPS 성장률Biotechs 이익 성장23.5%매출 성장률13.7%향후 자기자본이익률n/a애널리스트 커버리지Good마지막 업데이트22 May 2026최근 향후 성장 업데이트공시 • Feb 03+ 1 more updateTwist Bioscience Corporation Provides Earnings Guidance for the Second Quarter of 2026Twist Bioscience Corporation provided earnings guidance for the second quarter of 2026. For Second Quarter of fiscal 2026, the company expects total revenue of $107 million to $108 million, growth of approximately 16% year-over-year at the midpoint.Breakeven Date Change • Oct 02Forecast to breakeven in 2028The 6 analysts covering Twist Bioscience expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$750.0k in 2028. Average annual earnings growth of 51% is required to achieve expected profit on schedule.모든 업데이트 보기Recent updates공시 • May 06Twist Bioscience Corporation Expands Clonal Genes Offering to Include Long and Complex SequencesTwist Bioscience Corporation had expanded its clonal genes portfolio with the early access launch of Complex Genes. Synthesis of structurally complex and highly-engineered protein sequences to enable acceptance of approximately 99.5% of clonal gene orders and 99.9% of all DNA products. Complex synthesis capabilities to support further advancement of AI-enabled drug discovery and nucleic acid therapeutics. Sequences with complex elements have historically been difficult to produce at commercial scale. Leveraging its proprietary silicon-based DNA synthesis platform and improved downstream processes in manufacturing, automation, and sequencing, Twist can now reliably synthesize and deliver these previously out-of-reach complex sequences at scale. Complex sequence elements such as short tandem, inverted and long repeats, as well as high or low GC content and more, can be essential components of customers’ sequences in the development of nucleic acid therapeutics such as cell and gene therapies, mRNA therapies and more. The ability to synthesize complex sequences is also essential for AI-enabled drug discovery where researchers need their AI-generated sequences manufactured exactly, without adding a step to alter the sequences for manufacturability. By delivering genes with novel and complex structures combined with a transparent online ordering and tracking process, Twist enables customers to advance cutting edge research, empowering the development of new and next-generation therapeutics. Twist can synthesize and deliver complex sequences including short tandem repeats, inverted repeats, long repeats, homopolymers up to 30 base pairs and localized regions of high or low GC content. These are features commonly found in sequence elements such as advanced promoters, UTRs, ITRs, secondary structures and GS linkers. When customers submit sequences, they will receive a complexity score and a manufacturability score, for full transparency during the ordering process. Twist reliably delivers constructs ranging from 300 to 7,000 base pairs within 15 business days standard turnaround time, regardless of order scale or complexity. All Twist Clonal Genes can be cloned into a Twist catalog vector, or an onboarded vector of the customer’s choice.Reported Earnings • May 05Second quarter 2026 earnings released: US$0.71 loss per share (vs US$0.66 loss in 2Q 2025)Second quarter 2026 results: US$0.71 loss per share (further deteriorated from US$0.66 loss in 2Q 2025). Revenue: US$110.7m (up 19% from 2Q 2025). Net loss: US$44.0m (loss widened 12% from 2Q 2025). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.공시 • Apr 21Twist Bioscience Corporation to Report Q2, 2026 Results on May 04, 2026Twist Bioscience Corporation announced that they will report Q2, 2026 results Pre-Market on May 04, 2026Recent Insider Transactions • Feb 24Insider recently sold €1.7m worth of stockOn the 17th of February, Paula Green sold around 39k shares on-market at roughly €44.30 per share. This transaction amounted to 55% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €10m more than they bought in the last 12 months.공시 • Feb 10Twist Bioscience Corporation Launches Next-Generation Library Preparation Kits Powered by Proprietary EnzymesTwist Bioscience Corporation launched the Twist TrueAmp Library Preparation Kit and Twist PCR-Free WGS Library Preparation Kit, each designed to address a wide range of sample input, including low input and challenging sample types, to enable clinical research. The Twist TrueAmp Library Prep Kit brings a new level of exceptional performance to Twist's library preparation portfolio, with advantages enabled by Twist in-house developed enzymes, including a previously developed ligase as well as a newly developed polymerase. Engineered for next generation sequencing applications, the specialized TrueAmp polymerase maximizes coverage across typically hard-to- sequence regions of the genome, while maintaining high accuracy during DNA copying. The kit ensures high yields even from low- input or degraded starting samples, which minimizes amplification-introduced errors and results in more usable high-quality data. To streamline large-scale workflows, the Twist TrueAmp Library Prep kit has been validated with the Twist HT-UDI adapters system, allowing for up to 3,072 unique indexes as well as Twist UMI adapters, ensuring precise strand identification and efficient multiplexing. To serve customers across sequencing applications, Twist developed a complementary PCR-free version of the kit for researchers conducting whole genome sequencing (WGS). Leveraging Twist's engineered ligase, the Twist PCR-Free WGS library Preparation Kit efficiently converts starting DNA without bias commonly seen in whole genome sequencing. Precly optimized enzymatic fragmentation conditions deliver consistent outputs that maximize sequencing efficiency and improve data quality. The PCR-Free WGS Kit allows Twist to further serve customers using whole genome sequencing for approaches where low pass sequencing is sufficient, such as rare disease, while in parallel providing researchers working in areas that require deep sequencing, such as cancer, with panels and other tools to support their research.Recent Insider Transactions • Feb 08VP & Chief Accounting Officer recently sold €278k worth of stockOn the 4th of February, Robert Werner sold around 7k shares on-market at roughly €38.72 per share. This transaction amounted to 21% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €8.7m more than they bought in the last 12 months.Reported Earnings • Feb 03First quarter 2026 earnings released: US$0.50 loss per share (vs US$0.53 loss in 1Q 2025)First quarter 2026 results: US$0.50 loss per share (improved from US$0.53 loss in 1Q 2025). Revenue: US$103.7m (up 17% from 1Q 2025). Net loss: US$30.5m (loss narrowed 3.4% from 1Q 2025). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.공시 • Feb 03+ 1 more updateTwist Bioscience Corporation Provides Earnings Guidance for the Second Quarter of 2026Twist Bioscience Corporation provided earnings guidance for the second quarter of 2026. For Second Quarter of fiscal 2026, the company expects total revenue of $107 million to $108 million, growth of approximately 16% year-over-year at the midpoint.New Risk • Feb 02New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 5.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.1% average weekly change). Earnings are forecast to decline by an average of 5.7% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$98m net loss in 3 years). Significant insider selling over the past 3 months (€951k sold).공시 • Jan 12Twist Bioscience Corporation to Report Q1, 2026 Results on Feb 02, 2026Twist Bioscience Corporation announced that they will report Q1, 2026 results Pre-Market on Feb 02, 2026공시 • Jan 09Twist Bioscience Corporation, Annual General Meeting, Feb 05, 2026Twist Bioscience Corporation, Annual General Meeting, Feb 05, 2026.공시 • Dec 04Twist Bioscience Corporation Launches New Plasmid Preps to Enable Nucleic Acid Therapeutics ResearchTwist Bioscience Corporation launched research-grade Plasmid DNA Preps designed to support the advancement of pharmaceutical and biotech customers' pre-clinical studies. With animal origin-free (AOF) and transfection-grade preps and target yield options, Twist can support the nucleic acid therapeutics discovery and development process by ensuring consistently manufactured DNA, aligning with customer specifications and reducing variability and risk in their discovery programs. Customers entering the preclinical phase often have specific quality requirements, such as animal origin-free, and low, or endotoxin-free, for DNA that will be transferred into delicate cells. To meet these standards, Twist offers low and endotoxin-free transfection grade preps, as well as AOF preps available with TSE and BSE certificates for verification of quality standards. In addition, customers can receive target yields for prep sizes 4ug to 10ug to ensure consistent and precise mass in every prep. The platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead.Reported Earnings • Nov 15Full year 2025 earnings released: US$1.30 loss per share (vs US$3.60 loss in FY 2024)Full year 2025 results: US$1.30 loss per share (improved from US$3.60 loss in FY 2024). Revenue: US$376.6m (up 20% from FY 2024). Net loss: US$77.7m (loss narrowed 63% from FY 2024). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Europe.Recent Insider Transactions • Nov 05Co-Founder recently sold €853k worth of stockOn the 30th of October, Emily Leproust sold around 31k shares on-market at roughly €27.19 per share. This transaction amounted to 7.2% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €862k. Emily has been a net seller over the last 12 months, reducing personal holdings by €4.1m.공시 • Oct 23Twist Bioscience Corporation to Report Q4, 2025 Results on Nov 14, 2025Twist Bioscience Corporation announced that they will report Q4, 2025 results Pre-Market on Nov 14, 2025Recent Insider Transactions • Oct 10Co-Founder recently sold €862k worth of stockOn the 6th of October, Emily Leproust sold around 31k shares on-market at roughly €27.48 per share. This transaction amounted to 7.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Emily has been a net seller over the last 12 months, reducing personal holdings by €3.4m.Breakeven Date Change • Oct 02Forecast to breakeven in 2028The 6 analysts covering Twist Bioscience expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$750.0k in 2028. Average annual earnings growth of 51% is required to achieve expected profit on schedule.Board Change • Sep 15Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Director Trynka Blake was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Aug 20Twist Bioscience Corporation Launches Oncology DNA CGP Panel to Advance Precision Medicine with Customizable, Platform-Agnostic NGS SolutionTwist Bioscience Corporation launched the Twist Oncology DNA Comprehensive Genomic Profiling (CGP) Panel, a customizable, research-use-only solution designed to empower users to identify genomic alterations for a broad set of tumors, guide targeted therapy development and support clinical and translational oncology research. The Twist Oncology DNA CGP Panel was designed to serve a wide range of research groups including regional clinical labs, academic medical centers, and biopharma partners. The panel composition incorporates clinical research and includes a comprehensive and updated biomarker list covering 562 genes that incorporate all major tumor types. The panel's coverage spans genomic alterations and genomic signatures and can detect base institutions, insertions and deletions (indels), copy number variations (CNVs), gene rearrangements as well as measure tumor mutational burden (TMB) and microsatellite instability (MSI). This is paired with Twist high quality and easy-to-use library preparation and target enrichment workflows. Twist is collaborating with several analytics companies to provide a complete solution from sequencing to analysis.Reported Earnings • Aug 07Third quarter 2025 earnings released: EPS: US$0.34 (vs US$1.47 loss in 3Q 2024)Third quarter 2025 results: EPS: US$0.34 (up from US$1.47 loss in 3Q 2024). Revenue: US$96.1m (up 18% from 3Q 2024). Net income: US$20.4m (up US$106.0m from 3Q 2024). Profit margin: 21% (up from net loss in 3Q 2024). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Europe.공시 • Aug 07Twist Bioscience Corporation Appoints Trynka Shineman Blake to Its Board of Directors and Audit CommitteeTwist Bioscience Corporation announced the appointment of Trynka Shineman Blake to its board of directors. She will also serve as a member of the audit committee. Ms. Shineman Blake most recently served as chief executive officer of Vistaprint, a Cimpress company, and brings nearly three decades of experience across multiple strategic areas including corporate governance, customer experience, digital transformation and global marketing. Ms. Shineman Blake previously served as CEO of Vistaprint (a division of Cimpress) focused on building a better way for microbusinesses to promote themselves. Prior to her tenure as CEO of Vistaprint, she held various positions of increasing responsibility at Vistaprint, including president of North America, executive vice president of global marketing and chief customer officer. During her tenure at Vistaprint, Ms. Shineman Blake played a pivotal role in scaling the business from under $100 million to more than $1 billion in revenue. She aligned the organization under a customer-centric culture, led a comprehensive re-architecture of the company’s technology platform to accelerate the pace of product launches and nurtured an innovation portfolio that expanded Vistaprint’s offerings into new markets and services. Before Vistaprint, she held senior positions at PreVision Marketing, a boutique analytic and marketing agency (acquired by Valassis). Ms. Shineman Blake serves on the boards of several public and private companies, including Tripadvisor, Semrush, Captura, a Charlesbank company, and Steer. She previously served on the boards of Ally Financial Inc. and UBM, PLC; the Management Board of Vistaprint (Cimpress) and the Board of Trustees for the Mass Technology Leadership Council. Ms. Shineman Blake holds a B.A. in psychology from Cornell University and an M.B.A. from Columbia Business School.공시 • Aug 01Twist Bioscience Corporation Expands in Vivo Antibody Discovery Services with Launch of Humanized Transgenic Mouse ModelTwist Bioscience Corporation announced the launch of a humanized transgenic (HuTg) mouse model to expand and complement its offering of antibody discovery services and further streamline monoclonal antibody discovery. The HuTg mouse model generates robust immune responses and human antibody repertoires to accelerate lead discovery and optimization. By using this platform, the company enable Twist customers to identify fully human hits in weeks instead of months and streamlines translation into the clinic. This new offering expands and complements Twist's in vivo antibody discovery capabilities as it can be paired with Twist's DiversimAb mouse model to maximize epitope coverage and also paired with B cell screening platforms.공시 • Jul 14Twist Bioscience Corporation to Report Q3, 2025 Results on Aug 04, 2025Twist Bioscience Corporation announced that they will report Q3, 2025 results Pre-Market on Aug 04, 2025공시 • Jul 07Twist Bioscience Corporation Expands Express Delivery Turnaround Time to All Gene Fragments Regardless of FormatTwist Bioscience Corporation accelerated its Express turnaround time for all Twist Gene Fragments with a turnaround time starting at two business days for both adapters off and adaptors on configurations. Twist Gene Fragments are designed to simplify the process of ordering synthetic DNA by offering a reliable and cost-effective solution for researchers. Fragments ship within two to four business days, for one or tens of thousands of Gene Fragments. Twist provides flexible delivery formats including tubes, plates, normalization and resuspension, as well as adapter addition, without impact to turnaround time or cost. Twist will offer gene Fragments without adaptors as a standard offering, eliminating the fee previously charged for removing adaptors. At Twist, company deliver Gene Fragments quickly, with a typical processing time of just 2-4 business days before turning product over to the shipping carrier. This rapid turnaround time reflects the efficiency of facilities, ensuring orders are manufactured quickly and reliably. company platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead.이익 및 매출 성장 예측BIT:1TWST - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수9/30/2028594-45N/AN/A79/30/2027516-69N/AN/A99/30/2026447-127N/AN/A83/31/2026409-81-100-56N/A12/31/2025392-77-87-51N/A9/30/2025377-78-76-48N/A6/30/2025362-85-69-51N/A3/31/2025348-191-65-56N/A12/31/2024330-197-68-63N/A9/30/2024313-209-69-64N/A6/30/2024295-220-75-69N/A3/31/2024277-192-96-87N/A12/31/2023262-206-129-111N/A9/30/2023245-205-170-142N/A6/30/2023235-209-165-123N/A3/31/2023228-213-212-134N/A12/31/2022216-214-233-132N/A9/30/2022204-218-226-124N/A6/30/2022184-208-251-158N/A3/31/2022163-188-212-152N/A12/31/2021146-165-170-134N/A9/30/2021132-152-139-112N/A6/30/2021127-135-124-103N/A3/31/2021113-123-115-98N/A12/31/2020101-117-144-132N/A9/30/202090-140-152-142N/A6/30/202073-147-152-140N/A3/31/202066-147-153-139N/A12/31/201960-141N/A-101N/A9/30/201954-108N/A-88N/A6/30/201947-96N/A-81N/A3/31/201940-86N/A-76N/A12/31/201833-77N/A-72N/A9/30/201825-71N/A-66N/A6/30/201820-68N/A-61N/A9/30/201711-59N/A-51N/A9/30/20162-44N/A-39N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 1TWST 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: 1TWST 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: 1TWST 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: 1TWST 의 수익(연간 13.7%)이 Italian 시장(연간 5.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 1TWST 의 수익(연간 13.7%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 1TWST의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/25 16:11종가2026/05/25 00:00수익2026/03/31연간 수익2025/09/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Twist Bioscience Corporation는 14명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Catherine Ramsey SchulteBairdLuke SergottBarclaysGaurav GoparajuBerenberg11명의 분석가 더 보기
공시 • Feb 03+ 1 more updateTwist Bioscience Corporation Provides Earnings Guidance for the Second Quarter of 2026Twist Bioscience Corporation provided earnings guidance for the second quarter of 2026. For Second Quarter of fiscal 2026, the company expects total revenue of $107 million to $108 million, growth of approximately 16% year-over-year at the midpoint.
Breakeven Date Change • Oct 02Forecast to breakeven in 2028The 6 analysts covering Twist Bioscience expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$750.0k in 2028. Average annual earnings growth of 51% is required to achieve expected profit on schedule.
공시 • May 06Twist Bioscience Corporation Expands Clonal Genes Offering to Include Long and Complex SequencesTwist Bioscience Corporation had expanded its clonal genes portfolio with the early access launch of Complex Genes. Synthesis of structurally complex and highly-engineered protein sequences to enable acceptance of approximately 99.5% of clonal gene orders and 99.9% of all DNA products. Complex synthesis capabilities to support further advancement of AI-enabled drug discovery and nucleic acid therapeutics. Sequences with complex elements have historically been difficult to produce at commercial scale. Leveraging its proprietary silicon-based DNA synthesis platform and improved downstream processes in manufacturing, automation, and sequencing, Twist can now reliably synthesize and deliver these previously out-of-reach complex sequences at scale. Complex sequence elements such as short tandem, inverted and long repeats, as well as high or low GC content and more, can be essential components of customers’ sequences in the development of nucleic acid therapeutics such as cell and gene therapies, mRNA therapies and more. The ability to synthesize complex sequences is also essential for AI-enabled drug discovery where researchers need their AI-generated sequences manufactured exactly, without adding a step to alter the sequences for manufacturability. By delivering genes with novel and complex structures combined with a transparent online ordering and tracking process, Twist enables customers to advance cutting edge research, empowering the development of new and next-generation therapeutics. Twist can synthesize and deliver complex sequences including short tandem repeats, inverted repeats, long repeats, homopolymers up to 30 base pairs and localized regions of high or low GC content. These are features commonly found in sequence elements such as advanced promoters, UTRs, ITRs, secondary structures and GS linkers. When customers submit sequences, they will receive a complexity score and a manufacturability score, for full transparency during the ordering process. Twist reliably delivers constructs ranging from 300 to 7,000 base pairs within 15 business days standard turnaround time, regardless of order scale or complexity. All Twist Clonal Genes can be cloned into a Twist catalog vector, or an onboarded vector of the customer’s choice.
Reported Earnings • May 05Second quarter 2026 earnings released: US$0.71 loss per share (vs US$0.66 loss in 2Q 2025)Second quarter 2026 results: US$0.71 loss per share (further deteriorated from US$0.66 loss in 2Q 2025). Revenue: US$110.7m (up 19% from 2Q 2025). Net loss: US$44.0m (loss widened 12% from 2Q 2025). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.
공시 • Apr 21Twist Bioscience Corporation to Report Q2, 2026 Results on May 04, 2026Twist Bioscience Corporation announced that they will report Q2, 2026 results Pre-Market on May 04, 2026
Recent Insider Transactions • Feb 24Insider recently sold €1.7m worth of stockOn the 17th of February, Paula Green sold around 39k shares on-market at roughly €44.30 per share. This transaction amounted to 55% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €10m more than they bought in the last 12 months.
공시 • Feb 10Twist Bioscience Corporation Launches Next-Generation Library Preparation Kits Powered by Proprietary EnzymesTwist Bioscience Corporation launched the Twist TrueAmp Library Preparation Kit and Twist PCR-Free WGS Library Preparation Kit, each designed to address a wide range of sample input, including low input and challenging sample types, to enable clinical research. The Twist TrueAmp Library Prep Kit brings a new level of exceptional performance to Twist's library preparation portfolio, with advantages enabled by Twist in-house developed enzymes, including a previously developed ligase as well as a newly developed polymerase. Engineered for next generation sequencing applications, the specialized TrueAmp polymerase maximizes coverage across typically hard-to- sequence regions of the genome, while maintaining high accuracy during DNA copying. The kit ensures high yields even from low- input or degraded starting samples, which minimizes amplification-introduced errors and results in more usable high-quality data. To streamline large-scale workflows, the Twist TrueAmp Library Prep kit has been validated with the Twist HT-UDI adapters system, allowing for up to 3,072 unique indexes as well as Twist UMI adapters, ensuring precise strand identification and efficient multiplexing. To serve customers across sequencing applications, Twist developed a complementary PCR-free version of the kit for researchers conducting whole genome sequencing (WGS). Leveraging Twist's engineered ligase, the Twist PCR-Free WGS library Preparation Kit efficiently converts starting DNA without bias commonly seen in whole genome sequencing. Precly optimized enzymatic fragmentation conditions deliver consistent outputs that maximize sequencing efficiency and improve data quality. The PCR-Free WGS Kit allows Twist to further serve customers using whole genome sequencing for approaches where low pass sequencing is sufficient, such as rare disease, while in parallel providing researchers working in areas that require deep sequencing, such as cancer, with panels and other tools to support their research.
Recent Insider Transactions • Feb 08VP & Chief Accounting Officer recently sold €278k worth of stockOn the 4th of February, Robert Werner sold around 7k shares on-market at roughly €38.72 per share. This transaction amounted to 21% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €8.7m more than they bought in the last 12 months.
Reported Earnings • Feb 03First quarter 2026 earnings released: US$0.50 loss per share (vs US$0.53 loss in 1Q 2025)First quarter 2026 results: US$0.50 loss per share (improved from US$0.53 loss in 1Q 2025). Revenue: US$103.7m (up 17% from 1Q 2025). Net loss: US$30.5m (loss narrowed 3.4% from 1Q 2025). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.
공시 • Feb 03+ 1 more updateTwist Bioscience Corporation Provides Earnings Guidance for the Second Quarter of 2026Twist Bioscience Corporation provided earnings guidance for the second quarter of 2026. For Second Quarter of fiscal 2026, the company expects total revenue of $107 million to $108 million, growth of approximately 16% year-over-year at the midpoint.
New Risk • Feb 02New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 5.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.1% average weekly change). Earnings are forecast to decline by an average of 5.7% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$98m net loss in 3 years). Significant insider selling over the past 3 months (€951k sold).
공시 • Jan 12Twist Bioscience Corporation to Report Q1, 2026 Results on Feb 02, 2026Twist Bioscience Corporation announced that they will report Q1, 2026 results Pre-Market on Feb 02, 2026
공시 • Jan 09Twist Bioscience Corporation, Annual General Meeting, Feb 05, 2026Twist Bioscience Corporation, Annual General Meeting, Feb 05, 2026.
공시 • Dec 04Twist Bioscience Corporation Launches New Plasmid Preps to Enable Nucleic Acid Therapeutics ResearchTwist Bioscience Corporation launched research-grade Plasmid DNA Preps designed to support the advancement of pharmaceutical and biotech customers' pre-clinical studies. With animal origin-free (AOF) and transfection-grade preps and target yield options, Twist can support the nucleic acid therapeutics discovery and development process by ensuring consistently manufactured DNA, aligning with customer specifications and reducing variability and risk in their discovery programs. Customers entering the preclinical phase often have specific quality requirements, such as animal origin-free, and low, or endotoxin-free, for DNA that will be transferred into delicate cells. To meet these standards, Twist offers low and endotoxin-free transfection grade preps, as well as AOF preps available with TSE and BSE certificates for verification of quality standards. In addition, customers can receive target yields for prep sizes 4ug to 10ug to ensure consistent and precise mass in every prep. The platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead.
Reported Earnings • Nov 15Full year 2025 earnings released: US$1.30 loss per share (vs US$3.60 loss in FY 2024)Full year 2025 results: US$1.30 loss per share (improved from US$3.60 loss in FY 2024). Revenue: US$376.6m (up 20% from FY 2024). Net loss: US$77.7m (loss narrowed 63% from FY 2024). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Europe.
Recent Insider Transactions • Nov 05Co-Founder recently sold €853k worth of stockOn the 30th of October, Emily Leproust sold around 31k shares on-market at roughly €27.19 per share. This transaction amounted to 7.2% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €862k. Emily has been a net seller over the last 12 months, reducing personal holdings by €4.1m.
공시 • Oct 23Twist Bioscience Corporation to Report Q4, 2025 Results on Nov 14, 2025Twist Bioscience Corporation announced that they will report Q4, 2025 results Pre-Market on Nov 14, 2025
Recent Insider Transactions • Oct 10Co-Founder recently sold €862k worth of stockOn the 6th of October, Emily Leproust sold around 31k shares on-market at roughly €27.48 per share. This transaction amounted to 7.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Emily has been a net seller over the last 12 months, reducing personal holdings by €3.4m.
Breakeven Date Change • Oct 02Forecast to breakeven in 2028The 6 analysts covering Twist Bioscience expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$750.0k in 2028. Average annual earnings growth of 51% is required to achieve expected profit on schedule.
Board Change • Sep 15Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Director Trynka Blake was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Aug 20Twist Bioscience Corporation Launches Oncology DNA CGP Panel to Advance Precision Medicine with Customizable, Platform-Agnostic NGS SolutionTwist Bioscience Corporation launched the Twist Oncology DNA Comprehensive Genomic Profiling (CGP) Panel, a customizable, research-use-only solution designed to empower users to identify genomic alterations for a broad set of tumors, guide targeted therapy development and support clinical and translational oncology research. The Twist Oncology DNA CGP Panel was designed to serve a wide range of research groups including regional clinical labs, academic medical centers, and biopharma partners. The panel composition incorporates clinical research and includes a comprehensive and updated biomarker list covering 562 genes that incorporate all major tumor types. The panel's coverage spans genomic alterations and genomic signatures and can detect base institutions, insertions and deletions (indels), copy number variations (CNVs), gene rearrangements as well as measure tumor mutational burden (TMB) and microsatellite instability (MSI). This is paired with Twist high quality and easy-to-use library preparation and target enrichment workflows. Twist is collaborating with several analytics companies to provide a complete solution from sequencing to analysis.
Reported Earnings • Aug 07Third quarter 2025 earnings released: EPS: US$0.34 (vs US$1.47 loss in 3Q 2024)Third quarter 2025 results: EPS: US$0.34 (up from US$1.47 loss in 3Q 2024). Revenue: US$96.1m (up 18% from 3Q 2024). Net income: US$20.4m (up US$106.0m from 3Q 2024). Profit margin: 21% (up from net loss in 3Q 2024). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Europe.
공시 • Aug 07Twist Bioscience Corporation Appoints Trynka Shineman Blake to Its Board of Directors and Audit CommitteeTwist Bioscience Corporation announced the appointment of Trynka Shineman Blake to its board of directors. She will also serve as a member of the audit committee. Ms. Shineman Blake most recently served as chief executive officer of Vistaprint, a Cimpress company, and brings nearly three decades of experience across multiple strategic areas including corporate governance, customer experience, digital transformation and global marketing. Ms. Shineman Blake previously served as CEO of Vistaprint (a division of Cimpress) focused on building a better way for microbusinesses to promote themselves. Prior to her tenure as CEO of Vistaprint, she held various positions of increasing responsibility at Vistaprint, including president of North America, executive vice president of global marketing and chief customer officer. During her tenure at Vistaprint, Ms. Shineman Blake played a pivotal role in scaling the business from under $100 million to more than $1 billion in revenue. She aligned the organization under a customer-centric culture, led a comprehensive re-architecture of the company’s technology platform to accelerate the pace of product launches and nurtured an innovation portfolio that expanded Vistaprint’s offerings into new markets and services. Before Vistaprint, she held senior positions at PreVision Marketing, a boutique analytic and marketing agency (acquired by Valassis). Ms. Shineman Blake serves on the boards of several public and private companies, including Tripadvisor, Semrush, Captura, a Charlesbank company, and Steer. She previously served on the boards of Ally Financial Inc. and UBM, PLC; the Management Board of Vistaprint (Cimpress) and the Board of Trustees for the Mass Technology Leadership Council. Ms. Shineman Blake holds a B.A. in psychology from Cornell University and an M.B.A. from Columbia Business School.
공시 • Aug 01Twist Bioscience Corporation Expands in Vivo Antibody Discovery Services with Launch of Humanized Transgenic Mouse ModelTwist Bioscience Corporation announced the launch of a humanized transgenic (HuTg) mouse model to expand and complement its offering of antibody discovery services and further streamline monoclonal antibody discovery. The HuTg mouse model generates robust immune responses and human antibody repertoires to accelerate lead discovery and optimization. By using this platform, the company enable Twist customers to identify fully human hits in weeks instead of months and streamlines translation into the clinic. This new offering expands and complements Twist's in vivo antibody discovery capabilities as it can be paired with Twist's DiversimAb mouse model to maximize epitope coverage and also paired with B cell screening platforms.
공시 • Jul 14Twist Bioscience Corporation to Report Q3, 2025 Results on Aug 04, 2025Twist Bioscience Corporation announced that they will report Q3, 2025 results Pre-Market on Aug 04, 2025
공시 • Jul 07Twist Bioscience Corporation Expands Express Delivery Turnaround Time to All Gene Fragments Regardless of FormatTwist Bioscience Corporation accelerated its Express turnaround time for all Twist Gene Fragments with a turnaround time starting at two business days for both adapters off and adaptors on configurations. Twist Gene Fragments are designed to simplify the process of ordering synthetic DNA by offering a reliable and cost-effective solution for researchers. Fragments ship within two to four business days, for one or tens of thousands of Gene Fragments. Twist provides flexible delivery formats including tubes, plates, normalization and resuspension, as well as adapter addition, without impact to turnaround time or cost. Twist will offer gene Fragments without adaptors as a standard offering, eliminating the fee previously charged for removing adaptors. At Twist, company deliver Gene Fragments quickly, with a typical processing time of just 2-4 business days before turning product over to the shipping carrier. This rapid turnaround time reflects the efficiency of facilities, ensuring orders are manufactured quickly and reliably. company platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead.